Abstract |
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an osteoinductive protein that plays a pivotal role in bone growth and regeneration. Studies conducted in many mammalian species and, most recently, human clinical studies, have provided definitive evidence of the ability of rhBMP-2 to induce bone. The findings of these studies provide a rationale for investigating whether rhBMP-2 therapy will be clinically useful in orthopedic practice. Consequently, we have initiated a clinical research program to evaluate the safety and efficacy of rhBMP-2 therapy in open tibial fractures. A prospective observational study (involving no rhBMP-2 treatment) was conducted to define an appropriate patient population for rhBMP-2 clinical trials and has provided critical information related to the design and execution of future studies. The rhBMP-2 clinical trials include a small pilot feasibility study and several larger studies. Data from the pilot feasibility study have demonstrated that implantation of rhBMP-2 (combined with an absorbable collagen sponge) is surgically feasible and safe. Larger, multicenter clinical studies are now ongoing in the United States and abroad.
|
Authors | G E Riedel, A Valentin-Opran |
Journal | Orthopedics
(Orthopedics)
Vol. 22
Issue 7
Pg. 663-5
(Jul 1999)
ISSN: 0147-7447 [Print] United States |
PMID | 10418860
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study)
|
Chemical References |
- Bone Morphogenetic Proteins
- Recombinant Proteins
|
Topics |
- Accidents, Traffic
- Adult
- Aged
- Bone Morphogenetic Proteins
(administration & dosage)
- Combined Modality Therapy
- Evaluation Studies as Topic
- Feasibility Studies
- Female
- Follow-Up Studies
- Fracture Fixation, Internal
(methods)
- Fracture Healing
(drug effects, physiology)
- Fractures, Open
(drug therapy, surgery)
- Humans
- Male
- Middle Aged
- Pilot Projects
- Recombinant Proteins
- Tibial Fractures
(drug therapy, surgery)
- Treatment Outcome
|